REGENXBIO, which is developing gene therapies for rare diseases with a proprietary delivery platform, raised $139 million by offering 6.3 million shares at $22, above the originally proposed $17 to $19 range. REGENXBIO will list on the Nasdaq under the symbol RGNX. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as joint bookrunners on the deal.
